Literature DB >> 27469513

Effects of Ketamine and Ketamine Metabolites on Evoked Striatal Dopamine Release, Dopamine Receptors, and Monoamine Transporters.

Adem Can1, Panos Zanos1, Ruin Moaddel1, Hye Jin Kang1, Katinia S S Dossou1, Irving W Wainer1, Joseph F Cheer1, Douglas O Frost1, Xi-Ping Huang1, Todd D Gould2.   

Abstract

Following administration at subanesthetic doses, (R,S)-ketamine (ketamine) induces rapid and robust relief from symptoms of depression in treatment-refractory depressed patients. Previous studies suggest that ketamine's antidepressant properties involve enhancement of dopamine (DA) neurotransmission. Ketamine is rapidly metabolized to (2S,6S)- and (2R,6R)-hydroxynorketamine (HNK), which have antidepressant actions independent of N-methyl-d-aspartate glutamate receptor inhibition. These antidepressant actions of (2S,6S;2R,6R)-HNK, or other metabolites, as well as ketamine's side effects, including abuse potential, may be related to direct effects on components of the dopaminergic (DAergic) system. Here, brain and blood distribution/clearance and pharmacodynamic analyses at DA receptors (D1-D5) and the DA, norepinephrine, and serotonin transporters were assessed for ketamine and its major metabolites (norketamine, dehydronorketamine, and HNKs). Additionally, we measured electrically evoked mesolimbic DA release and decay using fast-scan cyclic voltammetry following acute administration of subanesthetic doses of ketamine (2, 10, and 50 mg/kg, i.p.). Following ketamine injection, ketamine, norketamine, and multiple hydroxynorketamines were detected in the plasma and brain of mice. Dehydronorketamine was detectable in plasma, but concentrations were below detectable limits in the brain. Ketamine did not alter the magnitude or kinetics of evoked DA release in the nucleus accumbens in anesthetized mice. Neither ketamine's enantiomers nor its metabolites had affinity for DA receptors or the DA, noradrenaline, and serotonin transporters (up to 10 μM). These results suggest that neither the side effects nor antidepressant actions of ketamine or ketamine metabolites are associated with direct effects on mesolimbic DAergic neurotransmission. Previously observed in vivo changes in DAergic neurotransmission following ketamine administration are likely indirect. U.S. Government work not protected by U.S. copyright.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27469513      PMCID: PMC5034706          DOI: 10.1124/jpet.116.235838

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  73 in total

Review 1.  Bupropion versus selective serotonin-reuptake inhibitors for treatment of depression.

Authors:  C E Nieuwstraten; L R Dolovich
Journal:  Ann Pharmacother       Date:  2001-12       Impact factor: 3.154

2.  Stability of ketamine and its metabolites norketamine and dehydronorketamine in human biological samples.

Authors:  Y Hijazi; M Bolon; R Boulieu
Journal:  Clin Chem       Date:  2001-09       Impact factor: 8.327

3.  NMDA receptor antagonists ketamine and PCP have direct effects on the dopamine D(2) and serotonin 5-HT(2)receptors-implications for models of schizophrenia.

Authors:  S Kapur; P Seeman
Journal:  Mol Psychiatry       Date:  2002       Impact factor: 15.992

4.  Behavioural, pharmacological and biochemical effects of acute and chronic administration of ketamine in the rat.

Authors:  B Lannes; G Micheletti; J M Warter; E Kempf; G Di Scala
Journal:  Neurosci Lett       Date:  1991-07-22       Impact factor: 3.046

5.  Safety and efficacy of repeated-dose intravenous ketamine for treatment-resistant depression.

Authors:  Marije aan het Rot; Katherine A Collins; James W Murrough; Andrew M Perez; David L Reich; Dennis S Charney; Sanjay J Mathew
Journal:  Biol Psychiatry       Date:  2010-01-15       Impact factor: 13.382

6.  Studies on the biotransformation of ketamine. 1-Identification of metabolites produced in vitro from rat liver microsomal preparations.

Authors:  J D Adams; T A Baillie; A J Trevor; N Castagnoli
Journal:  Biomed Mass Spectrom       Date:  1981-11

7.  Tonic activation of NMDA receptors causes spontaneous burst discharge of rat midbrain dopamine neurons in vivo.

Authors:  K Chergui; P J Charléty; H Akaoka; C F Saunier; J L Brunet; M Buda; T H Svensson; G Chouvet
Journal:  Eur J Neurosci       Date:  1993-02-01       Impact factor: 3.386

8.  Subthalamic nucleus modulates burst firing of nigral dopamine neurones via NMDA receptors.

Authors:  K Chergui; H Akaoka; P J Charléty; C F Saunier; M Buda; G Chouvet
Journal:  Neuroreport       Date:  1994-06-02       Impact factor: 1.837

9.  Pramipexole for bipolar II depression: a placebo-controlled proof of concept study.

Authors:  Carlos A Zarate; Jennifer L Payne; Jaskaran Singh; Jorge A Quiroz; David A Luckenbaugh; Kirk D Denicoff; Dennis S Charney; Husseini K Manji
Journal:  Biol Psychiatry       Date:  2004-07-01       Impact factor: 13.382

10.  The distribution and clearance of (2S,6S)-hydroxynorketamine, an active ketamine metabolite, in Wistar rats.

Authors:  Ruin Moaddel; Mitesh Sanghvi; Katina Sourou Sylvestre Dossou; Anuradha Ramamoorthy; Carol Green; James Bupp; Robert Swezey; Kathleen O'Loughlin; Irving W Wainer
Journal:  Pharmacol Res Perspect       Date:  2015-06-22
View more
  38 in total

1.  Computational Analysis of Therapeutic Neuroadaptation to Chronic Antidepressant in a Model of the Monoaminergic Neurotransmitter and Stress Hormone Systems.

Authors:  Mariam B Camacho; Warut D Vijitbenjaronk; Thomas J Anastasio
Journal:  Front Pharmacol       Date:  2019-10-25       Impact factor: 5.810

Review 2.  Ketamine and Ketamine Metabolite Pharmacology: Insights into Therapeutic Mechanisms.

Authors:  Panos Zanos; Ruin Moaddel; Patrick J Morris; Lace M Riggs; Jaclyn N Highland; Polymnia Georgiou; Edna F R Pereira; Edson X Albuquerque; Craig J Thomas; Carlos A Zarate; Todd D Gould
Journal:  Pharmacol Rev       Date:  2018-07       Impact factor: 25.468

Review 3.  Ketamine: The final frontier or another depressing end?

Authors:  Omar K Sial; Eric M Parise; Lyonna F Parise; Tamara Gnecco; Carlos A Bolaños-Guzmán
Journal:  Behav Brain Res       Date:  2020-02-01       Impact factor: 3.332

Review 4.  Hydroxynorketamines: Pharmacology and Potential Therapeutic Applications.

Authors:  Jaclyn N Highland; Panos Zanos; Lace M Riggs; Polymnia Georgiou; Sarah M Clark; Patrick J Morris; Ruin Moaddel; Craig J Thomas; Carlos A Zarate; Edna F R Pereira; Todd D Gould
Journal:  Pharmacol Rev       Date:  2021-04       Impact factor: 25.468

Review 5.  Convergent Mechanisms Underlying Rapid Antidepressant Action.

Authors:  Panos Zanos; Scott M Thompson; Ronald S Duman; Carlos A Zarate; Todd D Gould
Journal:  CNS Drugs       Date:  2018-03       Impact factor: 5.749

6.  MK801-induced locomotor activity in preweanling and adolescent male and female rats: role of the dopamine and serotonin systems.

Authors:  Sanders A McDougall; Matthew G Apodaca; Ginny I Park; Angie Teran; Timothy J Baum; Nazaret R Montejano
Journal:  Psychopharmacology (Berl)       Date:  2020-05-22       Impact factor: 4.530

Review 7.  Mechanisms of ketamine action as an antidepressant.

Authors:  P Zanos; T D Gould
Journal:  Mol Psychiatry       Date:  2018-03-13       Impact factor: 15.992

Review 8.  The neurobiology of depression, ketamine and rapid-acting antidepressants: Is it glutamate inhibition or activation?

Authors:  Chadi G Abdallah; Gerard Sanacora; Ronald S Duman; John H Krystal
Journal:  Pharmacol Ther       Date:  2018-05-25       Impact factor: 12.310

9.  Ketamine Pharmacokinetics and Pharmacodynamics Are Altered by P-Glycoprotein and Breast Cancer Resistance Protein Efflux Transporters in Mice.

Authors:  Samit Ganguly; John C Panetta; Jessica K Roberts; Erin G Schuetz
Journal:  Drug Metab Dispos       Date:  2018-04-19       Impact factor: 3.922

10.  Mouse, rat, and dog bioavailability and mouse oral antidepressant efficacy of (2R,6R)-hydroxynorketamine.

Authors:  Jaclyn N Highland; Patrick J Morris; Panos Zanos; Jacqueline Lovett; Soumita Ghosh; Amy Q Wang; Carlos A Zarate; Craig J Thomas; Ruin Moaddel; Todd D Gould
Journal:  J Psychopharmacol       Date:  2018-11-29       Impact factor: 4.153

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.